Human Genome Sciences, Inc. Announces Offering of Convertible Notes

ROCKVILLE, Md.--(BUSINESS WIRE)--Human Genome Sciences, Inc. (Nasdaq: HGSI) today announced its intention to offer, subject to market and other conditions, $400 million aggregate principal amount of its Convertible Senior Notes due 2018. The notes will be convertible, under certain circumstances, into cash, shares of the company’s common stock, or a combination, at the company’s election. The interest rate, conversion price and certain other terms of the offering are to be determined at the time of pricing. The company intends to grant the underwriter an option to purchase up to an additional $60 million aggregate principal amount of notes.